NCT07137104View on ClinicalTrials.gov

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

July 31, 2028

Conditions

Coronary Artery Disease

Interventions

DRUG

HeXell-2020

"Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose.~Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose.~Phase IIa: RP2D from phase I."